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UV-absorption and circular dichroism (CD) experiments showed that ellipticine derivatives may interact with DNA according to 3 possible binding 
modes depending on their structure and concentration. The first mode concerned intercalation of I-methyl-9-hydroxyellipticine (l-Me-HE) with 
its long axis perpendicular to the long axis of base pairs. The same drug was able to bind to external sites (second mode) once the intercalation 
sites were saturated at high concentration. The third mode illustrated by 1,2-dimethyl-9-hydroxyisoellipticinium (I-Me-isoNMHE), concerned self- 
stacked molecules interacting at the surface of DNA. Biological significance of these different binding modes was then discussed in connection 
with in vitro cytotoxic activity of compounds. 
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1. INTRODUCTION 
Research into drug action mode at the molecular level 
must be first concerned with the interaction of the drug 
with its receptor. Then come the events which link that 
interaction with the pharmacological response. As long 
as DNA can be regarded as the main target for an- 
ticancer drug action [l-3], the spectroscopic study of 
drug-DNA interaction remains highly important for a 
good understanding of drug action mechanism 141. 
We report results on the interaction of two 
derivatives of ellipticine (5,l l-dimethyl&H-pyrido- 
[4,3-blcarbazole) [S-l I], l-MeHE and 1-Me-isoNMHE 
(Fig. 1) with poly d(A-T) - poly d(A-T) chosen as a B- 
type DNA model. These compounds were selected as 
representatives of the 9-hydroxyellipticines and 
7-hydroxyisoellipticines. The two molecules bear thus 
an important hydroxy group on their leftern ring 
[12,13]. They differ however by the position of their 
pyridinic nitrogen atom. UV-absorption and circular 
dichroism experiments as well as in vitro cytotoxicity 
assays on L1210 leukemia cells were performed for this 
comparative work. 
tively. Poly d(A-T) . poly d(A-T) was obtained from Boehringer. We 
used an extinction coefficient of ~260 = 6700 M - ’ (Baby) . cm - ‘. 
Samples of poly d(A-T) . poly d(A-T) were prepared in 10 mM 
sodium phosphate buffer, e.g. at weak ionic strength (I = 0.02), pH 
7 with 0.2 mM EDTA. Titrations were performed by incrementally 
adding aliquots of 2 mM aqueous drug solutions to 2.5 ml of 65 PM 
poly d(A-T) . poly d(A-T) solutions, in 1 cm path-length quartz cells, 
and following UV-absorbance and CD signals at different 
wavelengths at 20°C. 
For cytotoxicity assays, exponentially growing L1210 murine 
leukemia cells seeded at 5 x 10’ cells/ml were incubated in 5% CO2 for 
72 h at 37°C in RPM1 1640 medium supplemented with 10% foetal 
calf serum, and drugs added at different concentrations. The results 
were expressed in IDSO (drug concentration inducing 50% cell growth 
inhibition). 
3. RESULTS AND DISCUSSION 
Fig. 2A and B show the UV absorption spectra ob- 
tained when poly d(A-T) - poly d(A-T) is titrated with 
l-Me-HE and l:Me-isoNMHE, respectively. In each 
figure, we inserted the corresponding free drug absorp- 
tion spectra. 
2. MATERIALS AND METHODS 
Absorption and CD spectra were recorded on a Uvicon 860 spec- 
trophotometer and on a Jobin-Yvon Mark IV high sensitivity 
dichrograph associated to a Mint Digital 11 miniprocessor, respec- 
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At low drug to DNA ratio, the signal originally 
observed at 305 nm is shifted at 323 nm (AX = + 18 nm) 
for l-Me-HE, and from 300 to 315 (Ax = + 15 nm) for 
I-Me-isoNMHE. Such an induced change is consistent 
with a binding occurring according to an intercalation 
mode (l-4). This signal grows up to r’ = 0.12 for l-Me- 
HE (r’ corresponds to the ratio of ligand to 
polynucleotide expressed in Base) while it reaches its 
maximum at r’ = 0.04 in the case of 1-Me-isoNMHE. 
Beyond these two r’ values a new peak arises at X = 305 
nm, e.g. at about the same wavelength where the free 
ellipticine derivatives themselves contribute. See for 
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Fig. 1. Structure of ellipticine derivatives 
comparison the inserted free drug spectra in Fig. 2A 
and B. Thus, because of the possible superposition of 
two contributions, this latter peak does not tell us too 
much on the binding ability of these two drugs at high 
r’ values. 
We resort then to CD experiments which can help to 
discriminate between the free molecules in solution and 
the molecules bound to DNA. The l-Me-HE and l-Me- 
isoNMHE derivatives lack chirality but optical activity 
can be conferred by insertion of the ~hromophore in the 
asymmetric enviro~ent of the DNA double helice 
while the unbound molecules remain optically silent. 
Fig. 3 shows the CD spectra obtained when poly d(A- 
T) - poly d(A-T) is titrated with l-Me-HE (a) and with 
1 -Me-isoNMHE (b). 
In the case of l-Me-HE a signal is induced, for r’ = 
O-O. 12, at X = 328 run, e.g. about the same wavelength 
as in the corresponding UV spectra (Fig. 2A). Thus, the 
CD and W measurements conclude to an intercalative 
binding mode for l-Me-HE at low drug to DNA ratio. 
260 280 300 320 3do 
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The simplicity of the positive CD signal (x = 328 nm) 
suggests that l-Me-HE intercalates with its chromo- 
phore plane parallel to the base pair planes and its long 
axis oriented perpendicularly to the long axis of the base 
pairs as demonstrated for intercalation of Methylene 
blue by Lyng et al. [14,15]. Existence of such a 
geometry is further proved by X-ray analysis of 
daunomycin and adriamycin in their crystallized eom- 
plexes with an hexanucleotide f16J. 
At a higher value (r’ > 0.12) a negative signal is in- 
duced at X = 310 nrn proving the binding of l-Me-HE 
to a new site. The signal position which appears only 
weakly shifted compared to that detected for the free 
drug in UV-absorption suggests an outside binding 
mode at high concentration for l-Me-HE (Figs 3A and 
2A). 
Addition of l-Me-isoNMHE to poly d(A-T) - poly 
d(A-T), after a very weak signal induction near 320 nm, 
generates rapidly excitonic spectra characterized by 
equally intense positive and negative signals at X = 310 
nmandX = 295 nm, respectively, and a change in sign 
at X = 303 run where the corresponding UV absorption 
signal is observed (Fig. 2B), These features may suggest 
Figs 2, W-absorption spectra of po& d(A-T) - poly d(A-T) titrated with: (A) I-Me-HE at r ’ = 0; 0.04; 0.08; 0.12; 0.2; 0.28; 0,39; and (B) l-Me- 
isoNMHE at r ’ = 0; 0.016; 0.046; 0.08; 0.12; 0.21; 0.31 (See text for definition of r’ and experimental ~o~d~t~o~~~. 
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Fig. 3. CD spectra of poly d(A-T) . poly d(A-T) titrated with: (A) I-Me-HE at r' = 0 (--); 0.04 (A A A); 0.08 (x x x x); 0.12 ( ••••• ); 
0.2 ( ..... ); 0.28 (----); 0.39 (-.-.); and (B) I-Me-isoNMHE at r' = 0 (-); 0.046 ( ..... ); 0.08 (----); 0.12 (-.-.); 0.21 (A A A); 0.31 (- .. -). 
an equilibrium between a large amount of self-stacked 
drugs bound to the surface of DNA (excitonic signal) 
and a small amount of drugs intercalated within base 
pairs (signal at A ::::: 320 nm). They further corroborate 
our results from topoisomerase I unwinding assays 
yielding unwinding angles of 11 0 and 17 0 for I-Me-
isoNMHE and I-Me-HE, respectively, and thus point-
ing out the weak intercalating ability of I-Me-
isoNMHE compared to I-Me-HE. In addition, only 
I-Me-HE displays a relatively high association constant 
(4 X 107 M -1) with poly d(A-T)· poly d(A-T) in our ex-
perimental conditions (work in progress). 
The results from the in vitro cytotoxicity assays in-
dicate that I-Me-HE with an ID50 < 0.1 X 10- 8 M, is 
highly cytotoxic while I-Me-isoNMHE, with an ID50 > 
50 x 10 - 8 M, is in comparison only poorly cytotoxic. 
Thus, the present results indicate that only the inter-
calating mode illustrated by I-Me-HE at low drug to 
DNA ratio is efficient toward the cytotoxic properties. 
It is clear that the nitrogen position in the pyridinic ring 
is important in this respect. 
To conclude, our results show that CD is useful to 
discriminate between the different binding modes of 
ellipticine derivatives to DNA. The results can be fur-
ther correlated to biological responses and models can 
be devised. 
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